Abivax is a French clinical-stage biopharmaceutical company focused on discovering, developing, and commercialising antiviral compounds and therapeutic vaccines for severe infectious diseases. It uses RNA-protein interaction interference and cytotoxic TH1 cell amplification to create therapies for clearing viruses like HIV, HBV, and HPV. Its product pipeline includes ABX 203, a therapeutic vaccine candidate for chronic hepatitis B, and ABX196, an adjuvant for therapeutic vaccines.